← Back to Clinical Trials
Recruiting NCT06367764

NCT06367764 A Comparative Effectiveness Study of PTSD Treatments Among Sexual and Gender Minority Populations

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06367764
Status Recruiting
Phase
Sponsor Stanford University
Condition PTSD
Study Type INTERVENTIONAL
Enrollment 400 participants
Start Date 2024-08-01
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cognitive Processing TherapySTAIR Narrative Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2024-08-01 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is see if Cognitive Processing Therapy and STAIR Narrative Therapy work to treat posttraumatic stress disorder (PTSD) among lesbian, gay, bisexual, transgender, queer/questioning, intersex, asexual/aromantic, and all other sexual or gender minority (LGBTQIA+) adults. The main questions it aims to answer are: * Do these treatments reduce PTSD symptoms in LGBTQIA+ patients? * Do these treatments help improve quality of life and reduce depression in LGBTQIA+ patients? * Do stress from stigma and discrimination and drug/alcohol use change the impact of the treatment on PTSD symptoms? * Are LGBTQIA+ patients satisfied with these treatments? Do these treatments work differently among different groups within the LGBTQIA+ community? * Do LGBTQIA+ patients complete these treatments? Study participants will receive one of these two PTSD treatments. Participants will complete assessments before and after receiving treatment.

Eligibility Criteria

Inclusion Criteria: 1. 18 years of age or older 2. Currently live in California 3. Ability to understand study procedures and to comply with them for the entire length of the study 4. Ability to understand a written informed consent document and the willing to sign it 5. Ability to speak and read English or Spanish 6. Identify as a sexual and/or gender minority 7. Score 33 or higher on the PTSD Checklist-5 (PCL-5) 8. Interest in getting treatment for PTSD 9. Not be in another concurrent psychotherapy treatment (group or individual) for PTSD (psychotherapy treatment for non-PTSD conditions is allowed). 10. Able to attend treatment sessions in person in San Francisco or have access to a device that allows for treatment via videoconferencing. Exclusion Criteria: 1. Contraindication to any study-related procedure or assessment 2. Clinically significant impairment which interferes with ability to fully participate in the study (including symptoms of schizophrenia, schizoaffective disorder, bipolar disorder, or other disorders) 3. Active suicidal intent

Contact & Investigator

Central Contact

Annesa P Flentje, PhD

✉ lgbtqia_study@ucsf.edu

📞 650-497-7112

Principal Investigator

Annesa P Flentje, PhD

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT06367764 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06367764 currently recruiting?

Yes, NCT06367764 is actively recruiting participants. Contact the research team at lgbtqia_study@ucsf.edu for enrollment information.

Where is the NCT06367764 trial being conducted?

This trial is being conducted at Palo Alto, United States, San Francisco, United States.

Who is sponsoring the NCT06367764 clinical trial?

NCT06367764 is sponsored by Stanford University. The principal investigator is Annesa P Flentje, PhD at Stanford University. The trial plans to enroll 400 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology